The mean of analysts' price targets for HOOKIPA Pharma (HOOK) points to a 622.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 634.4% in HOOKIPA Pharma (HOOK). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
HOOKIPA Pharma (HOOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.